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Abstract B-cell leukemia/lymphoma 2 (Bcl-2) blocks oxidant-
induced apoptosis at least partly by stabilizing lysosomes. Here
we report that phosphorylation of Bcl-2 may be required for these
protective effects. J774 cells overexpressing wild-type Bcl-2
resist oxidant-induced lysosomal leak as well as apoptosis, and
this protection is amplified by pretreatment with phorbol 12-
myristate 13-acetate (which promotes protein kinase C (PKC)-
dependent phosphorylation of Bcl-2). In contrast, cells over-
expressing the Bcl-2 mutant S70A (which cannot be phosphory-
lated) are not protected in either circumstance. Transfection with
Bcl-2(S70E), a constitutively active Bcl-2 mutant which does not
require phosphorylation, is protective independent of PKC
activation. In contrast, C2-ceramide, a putative protein phos-
phatase 2A activator, abolishes the protective effects of wild-type
Bcl-2 overexpression but does not diminish protection afforded
by Bcl-2(S70E). Additional results suggest that, perhaps as a
consequence of lysosomal stabilization, Bcl-2 may prevent
activation of phospholipase A2, an event potentially important
in the ultimate initiation of apoptosis. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
A short period of oxidative stress initiates lysosomal rup-
ture catalyzed by intra-lysosomal low molecular weight iron
which is normally present in lysosomes [1^5]. This rupture
seems to consist of two phases. The early one results in only
a limited release of lysosomal hydrolytic enzymes, while the
second one, that occurs even in the absence of continued oxi-
dative stress, leads to a much more pronounced lysosomal
breach and ensuing apoptosis [6^8]. This lysosomal leakage
may help initiate apoptosis; however, the precise mechanisms
are presently unknown. Among several possibilities, lysosomal
enzymes which are released to the cytosol may predispose to
apoptosis by (i) direct activation of pro-caspases [9,10],
(ii) attack on mitochondrial and lysosomal membranes result-
ing in release of pro-apoptotic cytochrome c and more lyso-
somal enzymes [6,11], (iii) activation of pro-apoptotic pro-
teins, such as Bid [12], or (iv) activation of lytic cytosolic
enzymes (such as phospholipase A2 (PLA2)) that, in turn,
attack mitochondrial and/or lysosomal membranes and fur-
ther propagate the process [6,13].
Overexpression of B-cell leukemia/lymphoma 2 (Bcl-2)
blocks the second, but not the ¢rst, phase of lysosomal rup-
ture [6], whereas both phases are prevented by pre-exposure of
cells to the potent iron chelator desferrioxamine. The endocy-
totic uptake of this chelator [14^16], and its almost exclusive
localization within the acidic vacuolar compartment, converts
the normal lysosomal pool of low molecular weight iron into
a redox-inactive form [2^5].
In contrast to desferrioxamine, the way in which Bcl-2 pro-
tects against (the second phase of) lysosomal rupture is far
from clear. Others have reported that Bcl-2 seems to be active
as an anti-apoptotic protein only as a phosphorylated homo-
dimer or when phosphorylated and complexed with Bcl-XL
[17^19]. We have, therefore, tested the importance of Bcl-2
phosphorylation in maintaining lysosomal stability and pre-
venting apoptosis using cells overexpressing a phosphoryla-
tion-negative Bcl-2 mutant [Bcl-2(S70A)], a phosphorylation-
equivalent mutant [Bcl-2(S70E)], or wild-type Bcl-2 [Bcl-
2(wt)]. We also induced phosphorylation/dephosphorylation
of Bcl-2(wt) in both parental and overexpressing cells. The
results indicate that phosphorylated ^ but not dephosphory-
lated ^ Bcl-2 suppresses both the second phase of lysosomal
rupture and prevents ensuing apoptosis. The results further
suggest that Bcl-2 may prevent activation of PLA2 by lysoso-
mal enzymes.
2. Materials and methods
2.1. Materials
Chemicals were purchased from Sigma (St. Louis, MO, USA) un-
less otherwise indicated. RPMI 1640 medium, fetal bovine serum,
glutamine, penicillin, and streptomycin were obtained from Gibco
BRL (Grand Island, NY, USA). The CaspACE FITC-VAD-FMK
In Situ Marker0 and the serine/threonine phosphatase kit were both
from Promega Corporation (Madison, WI, USA), while N-[1-(2,3-di-
oleoyl)propyl]-N,N,N-trimethyl-ammonium salt (DOTAP) was from
Boehringer Mannheim (Indianapolis, IN, USA). Monoclonal aga-
rose-conjugated anti-Bcl-2 antibodies (sc-7382 AC) were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and mono-
clonal anti-phosphoserine antibodies (clone PSR-45) were from Sig-
ma. The plasmids (see below) were kind gifts from Dr. W.S. May,
University of Texas, Medical Branch, Galveston, TX, USA.
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2.2. Cell cultures
J774 cells (a murine histiocytic lymphoma cell line) were maintained
in RPMI 1640 medium supplemented with 10% fetal bovine serum,
2 mM glutamine, 50 U/ml penicillin, 50 Wg/ml streptomycin, and 1%
non-essential amino acids. Cells were maintained in plastic £asks and
sub-cultivated at con£uence twice a week. For experiments, cells were
transferred into 35 mm 6-well plates (5U105 cells/well) 24 h before
use.
2.3. Preparation of transfected cell lines
Parental J774 cells were sub-cultivated into 6-well plates as de-
scribed above and transfected, using liposomal DOTAP delivery ac-
cording to the manufacturer’s directions, with the expression plasmids
(mouse) Bcl-2K(wt)/pMKITNeo, Bcl-2K(S70A)/pMKITNeo, Bcl-
2K(S70E)/pMKITNeo, and the empty vector pMKITNeo [17,20].
Each vector contains a neomycin resistance element (Neo). Ten stable
transfected clones of each line were selected by neomycin resistance
and their expression levels of exogenous Bcl-2 were assayed by West-
ern blot analysis (vide infra). Transfected clones which each had a
5-fold increase of immunoreactive Bcl-2 protein were selected, ex-
panded, and used for experiments. The three di¡erent Bcl-2 overex-
pressing J774 cell lines are hereafter named ‘J774-Bcl-2(wt)’, ‘J774-
Bcl-2(S70A)’, and ‘J774-Bcl-2(S70E)’, while the non-overexpressing
‘empty vector’ control cell line is named ‘J774-vector’.
2.4. Oxidative stress
Parental cells, J774-vector cells, and the three lines (wt, S70A and
S70E) of Bcl-2 overexpressing cells, were exposed for 1 h at 37‡C to a
steady-state concentration (40 WM) of H2O2 as described previously
[6,7,21]. To abruptly obtain this steady-state concentration of H2O2,
37 mU/ml glucose oxidase (1.5 Wg/ml) was added to complete medium
together with an initial bolus of H2O2 to bring the starting H2O2
concentration to 40 WM. Following 1 h of incubation under otherwise
standard culture conditions, catalase was added to clear the H2O2.
The cells were then quickly rinsed with sterile phosphate-bu¡ered sa-
line (PBS, 0.1 M NaCl, 0.002 M KCl, 0.01 M Na2HPO4, 0.001 M
KH2PO4, pH 7.4), and fresh complete medium was added.
2.5. Lysosomal stability assessment
Cells were assessed for lysosomal stability at di¡erent times follow-
ing oxidative stress using the acridine orange (AO) and lucifer yellow
(LY) uptake methods [2^4,6^8,11,15,22].
AO is a lysosomotropic base and a metachromatic £uorochrome
exhibiting red £uorescence when highly concentrated (as is the case in
intact lysosomes where AO is retained in its charged ^ AOH ^ form).
Lysosomal intactness was evaluated by assaying red £uorescence by
£ow cytometry [6,7,23], using a Becton-Dickinson FACScan (Becton-
Dickinson, Mountain View, CA, USA) equipped with a 488 nm argon
laser. Cells were analyzed following exposure to 5 Wg/ml AO for 15
min, under otherwise standard culture conditions, followed by a short
rinse (U2) in complete medium. After AO staining, cells were de-
tached by scraping with a rubber policeman and collected for £ow
cytometric assessment using the FL3 channel for red £uorescence.
CellQuest software was used to analyze the data.
Cells were grown on coverslips and exposed to LY (0.25 mg/ml
medium), a bright £uorochrome and a marker of endocytosis, for
1 h at otherwise standard culture conditions. The cells were then kept
for another 4 h in complete medium without the marker molecule (to
obtain selective labeling of secondary lysosomes) and then exposed to
oxidative stress as described above. Following this, the cells were
returned to standard culture condition for various periods of time
and, ¢nally, analyzed using a Nikon microphot-SA £uorescence
microscope (Nikon, Tokyo, Japan) equipped with a Hamamatsu
ORCA-100 color digital camera (Hamamatsu, Japan).
2.6. Apoptosis assessment assay
The DNA fragmentation (Nicoletti) assay is based on propidium
iodide staining of nuclear DNA and was performed essentially as
described elsewhere [24]. Brie£y, cell pellets from individual wells
were gently resuspended in 1.5 ml of a hypotonic and membrane-
disrupting solution of propidium iodide (50 Wg/ml in 0.1% sodium
citrate with 0.1% Triton X-100) in 12U75 mm polypropylene tubes.
The tubes were kept in the dark overnight at 4‡C before £ow cyto-
metric analyses. The propidium iodide-induced red £uorescence of
suspended individual nuclei was measured by £ow cyto£uorometry,
using the FL3 channel. Nuclei with partly degraded DNA were
counted and their frequency was expressed as percent of the total
number of analyzed nuclei (10 000).
Apoptosis was also evaluated by microscopical analysis of living
cells, initially stained according to the manufacturer’s directions
with a FITC-conjugated broad spectrum inhibitor of caspases, Casp-
ACE1 FITC-VAD-FMK In Situ Marker0 that irreversibly binds to
activated caspases. Brie£y, cells were seeded at 5U105 cells/ml, ex-
posed to oxidative stress as described above, and returned to standard
culture conditions for another 4 h. The marker was added to the
medium at a ¢nal concentration of 10 WM. The cells were incubated
in the dark for 20 min, rinsed (U3, 5 min in all) in PBS, and observed,
counted, and photographed using the above Nikon £uorescence
microscope.
2.7. Measurement of 3H-arachidonic acid (AA) release
(PLA2 activity)
Cells were labeled with 1.5 WCi/ml 3H-AA by incubation in serum-
free medium at 37‡C for 18 h as previously described [25]. Unincor-
porated 3H-AA was removed by washing (U3) with PBS. Cells were
then resuspended in fresh complete medium and exposed to oxidative
stress as described above. The culture medium was then replaced by
serum-free medium containing 1% fatty acid-free albumin and cells
were returned to standard culture conditions for another 8 h. Cells
were then scraped into their medium, and cells and fragments were
pelleted by centrifugation at 13 000Ug for 10 min. The supernatant
was chromatographed on Cibracron blue 3GA-agarose and retained
radioactivity (representing free AA bound to albumin) was eluted
using 0.1 M guanidine-HCl. Radioactivity was measured by scintilla-
tion counting. Counts from cells+medium, re£ecting total incorpora-
tion of 3H-AA into cell membrane phospholipids, were given the
value A, while counts from the eluted supernatant, considered to
re£ect AA released to the medium and bound to albumin, were given
the value B. The amount of released AA was expressed as B/AU100.
2.8. Protein phosphatase 2A (PP2A) assay
PP2A activity was determined on lysed cells by measuring the gen-
eration of inorganic phosphate (Pi) from the phosphorylated peptide,
RRA(pT)VA, using a molybdate-malachite green-phosphate complex
assay (serine/threonine phosphatase assay system) as described by the
manufacturer. Cell lysates were prepared in a detergent lysis bu¡er
(0.25% Nonidet P-40, 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
phenylmethylsulfonyl £uoride (PMSF), 10 Wg/ml aprotinin, 10 Wg/ml
leupeptin). The phosphatase assay was performed in a PP2A-speci¢c
reaction bu¡er (¢nal concentration 50 mM imidazole (pH 7.2), 0.2
mM ethylene glycol-bis-(L-aminoethyl ether)-N,N,NP,NP-tetraacetic
acid (EGTA), 0.02% 2-mercaptoethanol, 0.1 mg/ml bovine serum al-
bumin) using 100 WM phosphorylated peptide as a substrate/Wg cell
lysate protein. After a 30-min incubation at room temperature, mo-
lybdate-malachite green was added and Pi was measured by optical
density at 600 nM.
2.9. Western blot analysis
Approximately 106 J774-Bcl-2 cells were lysed by addition of 0.5 ml
of a solution containing 20 mM Tris^HCl, 120 mM NaCl, 10% glyc-
erol, 1 mM Na3VO4, 2 mM ethylenediaminotetraacetic acid (EDTA),
1% Triton X-100, 1 mM PMSF, pH 7.5. The lysate was incubated
with agarose-conjugated monoclonal anti-Bcl-2 antibodies overnight
and the agarose-conjugated immuno-complex was spun down
(500Ug, 5P). Bcl-2 and antibodies were separated on 12% sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^PAGE)
gels (2 h, 50 mA, room temperature) and transferred onto an Im-
mobilon0 membrane (2 h, 200 mA, 4‡C). Filters were then incubated
for 1 h at room temperature in blocking bu¡er (5% low-fat milk
powder in Tris-bu¡ered saline (TBS)) and then for another 2 h in
dilution bu¡er (0.5% low-fat milk powder in TBS) containing the
monoclonal anti-phosphoserine antibody (1:500). After washing
(TBS with 0.06% Tween 20), the membranes were incubated (1 h,
room temperature) in the above dilution bu¡er with peroxidase-con-
jugated secondary antibodies (1:1500). After washing, peroxidase-de-
pendent chemiluminescence was measured employing enhanced chem-
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iluminescence Western blotting reagents and hyper¢lm according to
the manufacturer’s instructions.
2.10. Statistical analysis
All experiments were repeated at least three times. Values are given
as arithmetic means þ S.D. Signi¢cance of di¡erences between groups
was determined using Student’s two-tailed t-test.
3. Results
Cells overexpressing Bcl-2(wt) were protected against
oxidant stress-induced lysosomal rupture assayed as numbers
of ‘pale cells’ following AO labeling (Fig. 1A) or cells
with reduced number of LY-positive granules (Fig. 1B). In
Fig. 1. Phosphorylation of Bcl-2 is required for protection against oxidative stress-induced lysosomal rupture. J774-vector cells and cells from
the Bcl-2-overexpressing cell lines, Bcl-2(wt), Bcl-2(S70A) and Bcl-2(S70E), were exposed to oxidative stress, as described in Section 2. After ex-
posure to oxidative stress for 1 h, cells were kept for another 8 h (A) under standard conditions before being exposed to AO and analyzed by
cyto£uorometry. M1 = ‘pale cells’ with reduced numbers of intact lysosomes. The J774-vector and J774-Bcl-2(S70A) groups did not di¡er
(Ps 0.05), while they were both signi¢cantly di¡erent from the J774-Bcl-2(wt) and J774-Bcl-2(S70E) (P6 0.01; n = 3 in each group). As an in-
dependent assessment of lysosomal intactness, other cells were initially stained with LY, as described in Section 2, then exposed to oxidative
stress for 1 h, returned to standard culture conditions for another 2 h and, ¢nally, analyzed by £uorescence microscopy (Fig. 2B). Results
shown are representative of three independent experiments.
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Fig. 2. PKC activity is crucial for stabilizing lysosomal membranes against oxidative stress. Parental J774 cells were pre-incubated with 100 nM
PMA for 2 h or 500 nM PMA for 48 h and Bcl-2 phosphorylation was assessed using a monoclonal anti-phosphoserine antibody (A). In addi-
tional experiments, the cells were incubated with or without PMA under the same conditions and then exposed to oxidative stress for 1 h and
then kept under standard culture conditions for another 8 h and exposed to AO (B). M1 = ‘pale cells’ with reduced numbers of intact lyso-
somes. The Ox-stress and the PMA (48 h)+Ox-stress groups were not signi¢cantly di¡erent (Ps 0.05), while both of these groups were signi¢-
cantly di¡erent from the untreated and the PMA (2 h)+Ox-stress groups (P6 0.01; n = 3 in each group). Alternatively, following 1 h oxidant
exposure the cells pre-incubated with LY were incubated an additional 2 h (C) as described in the legend to Fig. 1. Results presented in B and
C are representative of three independent experiments.
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contrast to the protective e¡ect of Bcl-2(wt), overexpression
of the mutant, site-speci¢c phosphorylation-negative
Bcl-2 (Bcl-2(S70A)) did not stabilize lysosomal membranes
against oxidative stress. On the other hand, overexpres-
sion of Bcl-2(S70E), which is active regardless of phosphory-
lation status, was at least as e¡ective as Bcl-2(wt) in confer-
ring protection against oxidant-induced lysosomal leak
(Fig. 1).
In indirect support of the importance of Bcl-2 phosphory-
lation, we found that short-term exposure of the parental J774
Fig. 3. Bcl-2 phosphorylation is associated with resistance to oxidative stress-induced apoptosis. Five groups of cells were tested: parental
cells þ 100 nM PMA for 2 h, cells overexpressing Bcl-2(wt), Bcl-2(S70A) or Bcl-2(S70E). All cells were exposed for 1 h to oxidative stress, as
described in Section 2, and then incubated under standard culture conditions for another 8 h (A). Finally, cells were assayed for apoptosis by
the Nicoletti method (A). The parental and Bcl-2(S70A) groups did not di¡er from each other (Ps 0.05), while each of them was signi¢cantly
di¡erent from each one of the other three groups (P6 0.01; n = 3 in each group). Alternatively, the cells were incubated 2 h following the 1 h
oxidant exposure and analyzed for caspase activation employing the CaspACE1 FITC-VAD-FMK In Situ Marker (B) as described in Section
2. Results shown in B are representative of three independent experiments. The number of FITC-VAD-FMK-positive cells corresponded almost
exactly with the frequencies of apoptotic cells shown in A.
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cells to the protein kinase C (PKC) activator phorbol 12-myr-
istate 13-acetate (PMA) enhanced Bcl-2 phosphorylation
while long-term PMA exposure, known to deplete active
PKC, suppressed Bcl-2 phosphorylation (Fig. 2A). Coinciding
with these e¡ects on Bcl-2 phosphorylation, short-term PMA
exposure made parental J774 cells resistant to oxidant-induced
lysosomal rupture, whether AO uptake or LY retention was
used as an indicator. In contrast, long-term PMA exposure
did not confer protection (Fig. 2B/C). Overall, these results
support the idea that phosphorylated ^ but not dephosphor-
ylated ^ Bcl-2 enhances lysosomal membrane stability in cells
challenged with an oxidant stress. Importantly, in all cases,
these Bcl-2-dependent di¡erences in lysosomal stability are
paralleled by changes in susceptibility to subsequent apopto-
sis.
The importance of Bcl-2 phosphorylation/activation is fur-
ther supported by investigations employing cells expressing
Bcl-2(S70A) (which cannot be phosphorylated and is inactive)
and S70E (which cannot be phosphorylated but is constitu-
tively active). As shown in Fig. 3, cells overexpressing Bcl-
2(S70A) show no protection against oxidant challenge where-
as those expressing Bcl-2(S70E) are as resistant as cells over-
expressing wild-type Bcl-2.
If, as the above results suggest, Bcl-2 phosphorylation is
required for both lysosomal membrane stabilization and sup-
pression of apoptosis, then activation of PP2A (with conse-
quent reduction in the level of Bcl-2 phosphorylation) should
sensitize to both lysosomal rupture and apoptosis. Indeed, we
¢nd that, as reported previously [18], pretreatment of target
cells with C2-ceramide enhances PP2A activity and that oka-
daic acid (OA), a known PP2A inhibitor, partly abrogates
PP2A activity (Fig. 4A). C2-ceramide-mediated activation of
PP2A abolished the protective e¡ect of Bcl-2(wt) overexpres-
sion on lysosomal integrity while inhibition of PP2A by OA
blocked the C2-ceramide e¡ect (Fig. 4B). Importantly, where-
as ceramide sensitized Bcl-2(wt) cells to lysosomal rupture and
apoptosis, it had no e¡ect on the phosphorylation-independ-
ent (and constitutively active) Bcl-2(S70E) expressing cells
(Fig. 4C).
While the foregoing results support the idea that phosphor-
ylated Bcl-2 does enhance lysosomal stability and suppress
apoptosis in oxidant-challenged cells, the mechanism(s) under-
lying these protective e¡ects are by no means clear. As pre-
viously mentioned, early and minor lysosomal rupture due to
oxidative stress is followed by a second, more extensive rup-
ture, even in the absence of continued oxidant exposure, sug-
gesting that the later rupture is a consequence of events other
than continuing oxidative stress [6^8]. In this regard, we re-
cently reported that activation of PLA2 may play an impor-
tant role in both lysosomal destabilization and ensuing apo-
ptosis, and that Bcl-2 may somehow prevent PLA2 activation
[6,8]. In further support of this, we ¢nd that PLA2 is not
activated in PMA-pretreated parental J774 cells, in Bcl-2(wt)
overexpressing cells or in cells overexpressing the constitu-
tively active (phosphorylation-independent) Bcl-2(S70E) (Fig.
5). Moreover, activation of PP2A by C2-ceramide in Bcl-2(wt)
overexpressing cells ^ earlier shown to block Bcl-2-dependent
protection against lysosomal rupture and apoptosis ^ restored
the activation of PLA2 normally seen in wild-type cells under-
going lysosomal rupture and apoptosis. Importantly, C2-cer-
amide had no such in£uence on AA release by cells expressing
the constitutively activated (phosphorylation-independent)
Bcl-2(S70E) (Fig. 5). Together, these data suggest that phos-
phorylated, but not dephosphorylated, Bcl-2 simultaneously
suppresses lysosomal leak, PLA2 activation and apoptosis in
oxidant-challenged J774 cells.
Fig. 4. Activation of PP2A abolishes the protective e¡ect of Bcl-2
on oxidative stress-induced lysosomal rupture. J774-Bcl-2(wt) and
J774-Bcl-2(S70E) cells were pretreated with 25 WM C2-ceramide, or
25 WM C2-ceramide together with 50 nM OA for 3 h. PP2A activity
was determined following this pre-incubation period (A). PP2A ac-
tivity was signi¢cantly increased (vs. control) following C2-ceramide
pretreatment (P6 0.01, n = 3) while cells pre-incubated with C2-cer-
amide+OA did not di¡er signi¢cantly from control. The cells were
then exposed to oxidative stress for 1 h and subsequently incubated
under standard culture conditions for another 8 h before being ex-
posed to AO (B) or propidium iodide (C), and analyzed by cyto-
£uorometry as described in Section 2. In B, M1 = ‘pale cells’ with
reduced numbers of intact lysosomes. Representative examples are
given of three independent experiments. In B and C, the C2-cer-
amide+Ox-stress group was signi¢cantly di¡erent from the other
two groups (P6 0.01; n = 3).
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4. Discussion
The term programmed cell death, or apoptosis, describes
the orchestrated collapse of a cell involving membrane bleb-
bing, cell shrinkage, protein fragmentation, chromatin con-
densation, DNA degradation, and segmentation into apopto-
tic bodies which are engulfed by macrophages or neighboring
cells [26]. Presently, many studies on apoptosis focus on mi-
tochondria and the release to the cytosol of mitochondrial
pro-apoptotic proteins, such as cytochrome c, apoptosis-in-
ducing protein (IAP) and the second mitochondria-derived
activator of caspase, direct IAP-binding protein with low pI
(smac/DIABLO) and ensuing activation of various pro-cas-
pases [27^31].
Lysosomal rupture is commonly regarded as a late event in
cell death and as a sign of necrosis. During the last few years,
however, an increasing number of reports have appeared sug-
gesting that lysosomal rupture with release of proteases such
as cathepsins B, L, H, and D may induce apoptosis. Thus, it
has been reported, for example, that cathepsin B contributes
to TNF-K-mediated hepatocyte apoptosis by promoting mito-
chondrial release of cytochrome c [32,33], while cathepsin L
was found to participate in the activation of caspase-3 [9,34],
and cathepsin D may be involved in apoptosis of several types
of cells [11,32,35^39]. Consequently, in the initiation of apo-
ptosis, the stability of the lysosomal membrane may be as
important as that of the mitochondrial membrane and lyso-
somal labilization may be a central and early upstream event
in apoptosis [13]. The present results, based on two independ-
ent methods to assay alterations in lysosomal stability of liv-
ing cells, lend further support to the concept that partial ly-
sosomal rupture is a starting signal for apoptosis.
Obviously, whether or not a cell undergoes apoptosis fol-
lowing a particular insult depends on complex interactions
between a host of anti- and pro-apoptotic proteins. In this
regard, proteins belonging to the Bcl-2 gene family may
have particularly potent roles [40]. The proteins in this family
are characterized by a considerable amino acid sequence ho-
mology [41,42], and have been found to regulate the forma-
tion of channels that facilitate protein (e.g. cytochrome c)
release from the mitochondria to the cytosol where pro-cas-
pase-9 is activated [40]. Interestingly, Bcl-2 has been observed
to regulate not only the permeability of the outer mitochon-
drial membrane but also that of the lysosomal membrane (C.
Borner, personal communication and results reported herein).
Recently, the importance of post-transcriptional modi¢ca-
tion of Bcl-2 has been raised [43]. The protein is known to be
phosphorylated and dephosphorylated in response to di¡erent
cell death stimuli [44], and Bcl-2 has been reported to act in an
anti-apoptotic fashion only in its phosphorylated form [17].
Multiple kinases have been implicated in the phosphorylation
of Bcl-2, including Raf-1 kinase, PKCK, protein kinase A, and
Jun N-terminal kinase/stress-activated protein kinase [20,45^
47]. However, the identity of the most important kinase(s) as
well as the functional signi¢cance of Bcl-2 phosphorylation in
the regulation of apoptosis remain poorly de¢ned. Bcl-2 phos-
phorylation has been related to both activation and inactiva-
tion of its anti-apoptotic function [43]. Of all kinases men-
tioned above, only PKCK has been reported to activate Bcl-
2 by phosphorylation (at serine 70), while other kinases may
inactivate it [17,20].
In order to extend our previous ¢nding that Bcl-2 stabilizes
lysosomal membranes in cells exposed to oxidative stress
[6,48], and thus prevents apoptosis, we have now studied the
activity of Bcl-2 in relation to its phosphorylation status. Our
data, obtained by transfection and overexpression of Bcl-2(wt)
and two mutant Bcl-2 forms, suggest that phosphorylation of
Bcl-2 secondary to PKC activation makes cells resistant to
oxidative stress, while PKC inactivation, or activation of
PP2A, makes cells more sensitive to oxidative stress with re-
sultant lysosomal rupture and ensuing apoptosis. These new
¢ndings lend further support to the suggestion that Bcl-2 may
stabilize lysosomes, and that this activity contributes to the
anti-apoptotic activity of this protein. Moreover, our results
provide additional ^ although still correlative ^ evidence that
lysosomal rupture is associated with the activation of PLA2.
This raises the possibility that activated PLA2 may act to
further destabilize the membranes of intracellular organelles
(such as lysosomes and mitochondria), thereby promoting the
cascade of events known as apoptosis. In this cascade, lyso-
somal breach may be an early upstream phenomenon.
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